TESARO (TSRO) Phase 3 NOVA Trial of Niraparib Achieves Primary Endpoint
Tweet Send to a Friend
TESARO, Inc. (NASDAQ: TSRO) announced that the Phase 3 NOVA trial of niraparib successfully achieved its primary endpoint of progression-free ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE